RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES
H7534 would authorize licensed pharmacists in Rhode Island to prescribe and dispense FDA-approved tobacco cessation drug therapies to eligible patients, subject to rules adopted by the Board of Pharmacy and approved by the Department of Health. To qualify, a patient must generally be at least 18 years old (or meet any FDA minimum-age guidance), agree to participate in a structured cessation program with initial and follow-up pharmacist visits, and be educated about nicotine toxicity and medication risks. Pharmacists would need to complete approved tobacco cessation training, follow updated clinical practice guidelines, and refer or consult with a patient’s primary care provider when appropriate, especially for high-risk patients or contraindications. The bill also requires pharmacists to notify the patient’s primary care provider of screening, prescriptions, and follow-up care plans within five business days.
The bill further requires coverage of pharmacist services by group health insurance contracts, nonprofit hospital service corporations, nonprofit medical service corporations, and HMOs for services within a pharmacist’s lawful scope of practice when the same service would be covered if performed by a physician, advanced practice nurse, or physician assistant. It bars insurers from requiring supervision, signature, or referral by another provider as a condition of reimbursement to a pharmacist, while also preventing payment for duplicative services. The bill also requires health plans to include an adequate number of pharmacists in their provider networks and extends coverage outside the network when the service is unavailable in-network. Tobacco cessation drug therapies would also be covered by Medicaid once a Section 1115 waiver is approved. The act would take effect upon passage, with insurance coverage provisions applying to policies renewed or issued on or after January 1, 2027.
This bill would amend Rhode Island’s pharmacy and insurance statutes by creating a new pharmacist prescriptive authority for tobacco cessation therapies and by expanding insurance reimbursement rules for pharmacist-delivered services. It adds new sections to the pharmacy law and to the chapters governing accident and sickness insurance policies, nonprofit hospital service corporations, nonprofit medical service corporations, and HMOs. The measure would also affect Medicaid coverage, contingent on approval of a Section 1115 demonstration waiver, and would require regulatory action by the Board of Pharmacy and the Department of Health to implement standards, training, and patient eligibility rules.
Based on the bill text and the absence of recorded committee testimony or votes, the measure appears to be framed as a public health and access-to-care bill with a generally supportive policy orientation. Its structure suggests an effort to expand smoking cessation treatment options and improve reimbursement for pharmacist services, which typically aligns with healthcare access and preventive care goals. No recorded votes or transcripts are available here to indicate formal opposition or support, so the overall sentiment can only be inferred from the bill’s purpose and drafting.
The main likely points of contention are scope of practice and insurance reimbursement. Pharmacists are granted authority to prescribe tobacco cessation medications, but only after completing approved education and following consultation/referral requirements for high-risk or contraindicated patients, which may reflect concern about patient safety and coordination with physicians. Insurers may also object to being required to cover pharmacist services, include pharmacists in networks, and reimburse without supervision or referral requirements, especially where they believe services could be duplicative or outside existing provider arrangements. Medicaid coverage is also contingent on a federal waiver, which could be another practical or policy hurdle.